Technical Analysis for ASRT - Assertio Therapeutics, Inc.

Grade Last Price % Change Price Change
C 0.853 -10.21% -0.10
ASRT closed down 10.21 percent on Friday, February 26, 2021, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Mar 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ASRT trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -10.21%
NR7 Range Contraction -10.21%
Inside Day Range Contraction -10.21%
Wide Bands Range Expansion -10.21%
20 DMA Support Bullish -12.19%
Wide Bands Range Expansion -12.19%
Older End-of-Day Signals for ASRT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% 2 days ago
Down 5% 2 days ago
Down 3% 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Assertio Therapeutics, Inc. Description

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pain Organ Systems Chemical Compounds Organic Compounds Opioid Analgesics Potassium Neuropathic Pain Acute Pain Migraine Treatment Of Migraine Amino Acids Diabetic Peripheral Neuropathy Peripheral Neuropathy Diclofenac Postherpetic Neuralgia

Is ASRT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.45
52 Week Low 0.33
Average Volume 17,785,621
200-Day Moving Average 0.73
50-Day Moving Average 0.69
20-Day Moving Average 0.96
10-Day Moving Average 1.04
Average True Range 0.14
ADX 40.55
+DI 28.61
-DI 22.11
Chandelier Exit (Long, 3 ATRs ) 1.02
Chandelier Exit (Short, 3 ATRs ) 1.04
Upper Bollinger Band 1.32
Lower Bollinger Band 0.60
Percent B (%b) 0.35
BandWidth 75.63
MACD Line 0.08
MACD Signal Line 0.11
MACD Histogram -0.0361
Fundamentals Value
Market Cap 91.46 Million
Num Shares 107 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -13.98
Price-to-Sales 0.29
Price-to-Book 0.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.00
Resistance 3 (R3) 1.02 0.98 0.98
Resistance 2 (R2) 0.98 0.95 0.97 0.97
Resistance 1 (R1) 0.92 0.92 0.90 0.90 0.96
Pivot Point 0.89 0.89 0.88 0.88 0.89
Support 1 (S1) 0.82 0.85 0.80 0.80 0.75
Support 2 (S2) 0.79 0.82 0.78 0.74
Support 3 (S3) 0.72 0.79 0.73
Support 4 (S4) 0.71